See more : SSY Group Limited (2005.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Mural Oncology plc (MURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mural Oncology plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AS PARTNERS CO LTD (160A.T) Income Statement Analysis – Financial Results
- Swicorp Wabel Reit Fund (4345.SR) Income Statement Analysis – Financial Results
- Tunghsu Azure Renewable Energy Co.,Ltd. (000040.SZ) Income Statement Analysis – Financial Results
- Learn CW Investment Corporation (LCW-UN) Income Statement Analysis – Financial Results
- Sabre Resources Limited (SBR.AX) Income Statement Analysis – Financial Results
Mural Oncology plc (MURA)
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.57M | 1.54M | 1.47M |
| Gross Profit | -2.57M | -1.54M | -1.47M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 162.03M | 170.07M | 159.82M |
| General & Administrative | 30.71M | 25.08M | 15.55M |
| Selling & Marketing | -667.00K | 0.00 | 0.00 |
| SG&A | 30.04M | 25.08M | 15.55M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 192.07M | 195.15M | 175.37M |
| Cost & Expenses | 194.64M | 195.15M | 175.37M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.57M | 1.54M | 1.47M |
| EBITDA | -192.72M | -183.38M | -173.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -194.64M | -195.15M | -175.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -649.00K | 10.22M | 0.00 |
| Income Before Tax | -195.29M | -195.15M | -175.37M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.16M | 4.88M | 68.00K |
| Net Income | -207.45M | -200.03M | -175.43M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -12.43 | -11.99 | -10.51 |
| EPS Diluted | -12.43 | -11.99 | -10.51 |
| Weighted Avg Shares Out | 16.69M | 16.69M | 16.69M |
| Weighted Avg Shares Out (Dil) | 16.69M | 16.69M | 16.69M |
Mural Oncology to Present at Two Upcoming Investor Conferences
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural's lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address...
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers,...
Source: https://incomestatements.info
Category: Stock Reports